References

References

  1. Jemal, A., et al., Cancer statistics, 2010. CA Cancer J Clin, 2010. 60(5): p. 277-300.
  2. Moore RG. and R.C. Bast, Jr., How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above. J Clin Oncol, 2007. 25(27): p. 4159-61
  3. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
  4. Danforth's Obstetrics and Gynecology, ed. B.Y.K. Ronald S. Gibbs, Arthur F. Haney, Ingrid Nygaard. 2008: Lippincott Williams & Wilkins.
  5. ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol, 2002. 100(6): p. 1413-6.
  6. Ovarian Cancer National Alliance. Risk Factors. [cited 2012 January 12]; Available from: http://www.ovariancancer.org/about-ovarian-cancer/risk-factors/.
  7. Moore RG, Brown AK, Miller CM, et al. The use of multiple novel serum tumor markers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108(2):402-408.
  8. Moore, R.G., et al., Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol, 2011. 118(2 Pt 1): p. 280-8.
  9. Guidelines for referral to a gynecologic oncologist: rationale and benefits. The Society of Gynecologic Oncologists. Gynecol Oncol. 2000;78(3 Pt 2):S1-S13.
  10. Bristow, R.E., et al., Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis. Cancer, 2007. 109(8): p. 1513-22.
  11. Giede, K.C., et al., Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol, 2005. 99(2): p. 447-61.
  12. NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA. 1995;273(6):491-497.
  13. HE4 Package Insert.
  14. FDI Data on File.
  15. Rice VM. Conventional medical therapies for endometriosis. Ann N Y Acad Sci 2002;955:343–52.
  16. http://www.mayoclinic.com/health/endometriosis/DS00289. Accessed on January 18, 2012
  17. Huhtinen K, Suvitie P, Hiissa J, et al. Serum HE4 concentration differentiates malignant ovarian tumors from ovarian endometriotic cysts. Br J Cancer. 2009; 100:1315-1319.
  18. Knapp RC, Jacobs I, Schwartz, P. Clinical perspectives on the use of the CA125 radioimmunoassay in ovarian cancer. Contemp Ob Gyn. 1996;41:99.
  19. American Cancer Society. What are the key statistics about ovarian cancer? http://www.cancer.org/Cancer/OvarianCancer/DetailedGuide/ovarian-cancer-key-statistics. Accessed January 18, 2012.
  20. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynecol Obstet. 2000;70(2):209-262.
  21. Moore RG, et al. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol. 2012 Apr;206(4):351.e1-8.